Transcatheter Interventions Online 2022 - On Demand
Published: 09 March 2022
Part 1 | Session 5 Session 1.4: Live Cases and Discussions
Part 1 | Session 6 BREAKOUT: Current Data and Future Direction in LAAC
Part 2 | Session 1 Session 2.1: Strategies for Calcified Coronary Lesions Anno 2022
Part 2 | Session 2 Session 2.2: Live Cases and Discussion
Part 2 | Session 4 Session 2.3: Practical Pearls Towards a More Advanced CTO Programme
Part 2 | Session 5 Session 2.4: Live Cases and Discussion
Part 2 | Session 7 BREAKOUT: Coronary Physiology in STEMI patients today: Why? When? How?
Part 1 | Session 1 Session 1.1: Next Level Structural Heart Interventions Nicolas M Van Mieghem, Kendra J Grubb, Lars Søndergaard, Azeem Latib, David Hildick-Smith
Part 1 | Session 2 Session 1.2: Live Cases and Discussion Lars Søndergaard, Ole De Backer, Holger Thiele, Nicolas M Van Mieghem, Azeem Latib, Kendra J Grubb, David Hildick-Smith, Mohamed Abdel-Wahab
Part 1 | Session 3 Symposium: Optimising Outcomes for the TAVI Patient: Key Considerations for First Valve Choice and Implantation Techniques Didier Tchétché, Lars Søndergaard, Ran Kornowski, Douglas G Fraser
Following on from the success of 2021's inaugural edition, Transcatheter Interventions Online 2022 brings together a world-class faculty to provide expert insight and educational learning on the latest developments in interventional management.
Combining expert opinion and discussion, presentations, and live cases from centres on both sides of the Atlantic, TIO 2022 delivers best-in-class learning, supporting the latest in diagnosis, treatment strategies and patient management.
Note, the live version of this session was CME accredited; this on-demand version is not.
Key Learning Objectives
- Describe the practical implications of TAVI in the context of coronary artery disease, atrioventricular valve disease and transcatheter heart valve degeneration
- Select appropriate tools for calcified coronary artery disease, including mechanical circulatory support and invasive imaging techniques
- Understand coronary physiology, novel recanalization and goal-oriented planning for chronic total occlusion
- Evaluate the role of novel oral anticoagulants in transcatheter aortic valve implantation
- Discuss the need for gender-specific trials and renal denervation
- Interventional Cardiologists
- Surgeons with an interest in transcatheter treatment strategies for coronary and structural heart disease
- Interventional Cardiology Nurses
More from this programme
Day One: Structural Heart Disease
Day Two: Coronary Heart Disease: High Risk & Complex PCI
Day Three: Debates and Controversies
Kendra J Grubb
Dr Kendra Grubb is the surgical director of the structural heart and valve center at Emory Healthcare. She is also an associate professor of surgery at Emory University School of Medicine.
Kendra is a champion for women's heart disease and is dedicated to improving the lives of all patients through innovation, collaboration and a patient-centered approach to the treatment of cardiovascular disease.
After obtaining her BS in Biology from the University of Southern California (1999), Kendra attended the University of Southern California, where she received her a master’s in health administration from the Sol Price School of Public Policy (2001), followed by an MD degree at the Keck School of Medicine (2005).
She pursued a general surgery residency at the University of Illinois at Chicago between 2005 and 2010, a fellowship in…
Didier Tchétché, (Clinique Pasteur, Toulouse, France) Graduated from the University of Paris V where Dr Tchétché obtained his post-graduate diploma of cardiovascular pathology in 2004. From 2004 to 2005, he completed a 12-month fellowship period in the Hemodynamic and Interventional Cardiology department of Clinique Pasteur in Toulouse and from 2005 to 2007 he was Head Assistant at the intensive care unit of Bichât Hospital in Paris.
In 2008, he joined the interventional cardiovascular group in Clinique Pasteur, Toulouse, and he is currently Head of the Structural programme with an experience of more than 5000 TAVI procedures. His main areas of interest are coronary interventions and valvular heart disease. He has been actively involved in many clinical trials involving new technologies and devices in the field of interventional cardiology.
Professor of Medicine, Cardiology and Professor of Population Health Science and Policy
Roxana Mehran is Professor of Medicine, Cardiology and Professor of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai in New York. She is also Director of Interventional Cardiovascular Research and Clinical Trials at The Zena and Michael A Weiner Cardiovascular Institute at Mount Sinai Hospital where, over the past 5 years, she has led the development of a globally respected data and clinical coordination centre to support large, multicentre, multinational clinical trials designed to help improve outcomes and quality of life for patients undergoing interventional cardiovascular procedures. In recent years, her work has had a special emphasis on gaining a deeper understanding of anticoagulation and antiplatelet regimens post angioplasty and transcatheter valve replacement; and collection and interpretation of sex-specific data in cardiovascular clinical trials.
Roxana serves on editorial board of multiple peer reviewed journals, including …
Prof David Hildick-Smith is Professor of Interventional Cardiology and Consultant Cardiologist at the Sussex Cardiac Centre - the Regional Specialist Unit. He is Director of the Cardiac Research, ex-Treasurer of the British Cardiovascular Interventions Society, and, with more than 20 years experience of Interventional Cardiology, is considered one of the country's leading experts in management of Cardiovascular complaints.
A pioneer of Interventional Cardiology, David is recognised internationally as a leader in cardiovascular diagnosis and treatment.
Professor Lars Søndergaard is a consultant cardiologist at Rigshospitalet – Copenhagen, Denmark. Professor of Cardiology at University of Copenhagen, he published over 300 peer reviewed articles, and more than 15 textbook chapters. His research interests are focused on adults with congenital heart diseases and catheter-based heart valve interventions, as well as congenital and structural heart diseases. He led the first-in-human transcatheter mitral valve implantation (CardiAQ) in 2012 and he actively participated to several trials, including NOTION (transcatheter vs. surgical aortic valve replacement in patients with aortic stenosis and low surgical risk), and the REDUCE randomised trial (PFO vs anti-platelet therapy after cryptogenic stroke).